Jeffrey Wolf, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue, #A454
San Francisco CA 94117
PronounsHe/Him/His
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine

    Collapse Overview 

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024 10 16; 14(1):180. Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Morán-Segura CM, Nguyen JV, Lekakis L, Fernandez-Pol S, Samraj AN, Naresh KN, Vazquez-Martinez M, Baz RC, Spiegel JY, Mikkilineni L, Gubatan JM, Sidana S, de Menezes Silva Corraes A, Kalariya NM, Patel KK, Shim KG, Fonseca R, Ferreri C, Voorhees PM, Richard S, Valdes CR, Wolf JL, Cowan AJ, Sborov DW, Locke FL, Lin Y, Wang Y, Hansen DK. PMID: 39414769; PMCID: PMC11484697.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024 07 09; 8(13):3562-3575. Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek S, Cheung A, Bylsma S, Hansen E, Wolf J, Wong S, Shah N, Roybal KT, Martin T, Ye CJ, Fong L. PMID: 38574299; PMCID: PMC11319832.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    3. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Blood Adv. 2024 05 14; 8(9):2207-2216. Reyes KR, Liu YC, Huang CY, Banerjee R, Martin T, Wong SW, Wolf JL, Arora S, Shah N, Chari A, Chung A. PMID: 38429087; PMCID: PMC11061209.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    4. Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma. Leuk Lymphoma. 2023 Nov-Dec; 64(11):1888-1891. Duvalyan E, Shah N, Lo M, Martin T, Wolf JL, Chung A, Arora S, Huang CY, Wong SW. PMID: 37599633.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    5. Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias. Br J Haematol. 2022 Nov; 199(4):520-528. Chung A, Banbury B, Vignali M, Huang CY, Asoori S, Johnson R, Kurtz T, Arora S, Wong SW, Shah N, Martin TG, Wolf JL. PMID: 36041779; PMCID: PMC9538250.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    6. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun. 2022 07 15; 13(1):4121. Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD, Mullins RD, Eyquem J, Wells JA, Wiita AP. PMID: 35840578; PMCID: PMC9287322.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    7. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022 04 12; 6(7):2045-2054. Kambhampati S, Sheng Y, Huang CY, Bylsma S, Lo M, Kennedy V, Natsuhara K, Martin T, Wolf J, Shah N, Wong SW. PMID: 34543400; PMCID: PMC9006279.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    8. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021 12 14; 5(23):5344-5348. Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf J, Martin TG, Shah N, Wong SW. PMID: 34644387; PMCID: PMC9153014.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    9. Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series. Clin Transplant. 2022 03; 36(3):e14541. Dinh AR, Wong SW, Martin TG, Wolf JL, Webber AB. PMID: 34797567.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma. J Immunother Cancer. 2021 07; 9(7). Sun H, Martin TG, Marra J, Kong D, Keats J, Macé S, Chiron M, Wolf JL, Venstrom JM, Rajalingam R. PMID: 34272304; PMCID: PMC8287616.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    11. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer. 2021 06 01; 127(11):1816-1826. Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A. PMID: 33735504; PMCID: PMC8252002.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    12. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2021 06; 27(6):477.e1-477.e7. Banerjee R, Marsal J, Huang CY, Lo M, Thiruvengadam SK, Kennedy VE, Arora S, Wolf JL, Martin TG, Wong SW, Shah N. PMID: 33831353.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    13. Benzodiazepine and zolpidem prescriptions during autologous stem cell transplantation. EJHaem. 2021 May; 2(2):276-279. Banerjee R, Lazar AA, Dunn L, Knoche J, Lo M, Arora S, Wong SW, Wolf JL, Martin TG, Dhruva A, Shah N. PMID: 35845271; PMCID: PMC9175938.
      View in: PubMed   Mentions: 3  
    14. Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation. J Geriatr Oncol. 2021 05; 12(4):531-539. Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL. PMID: 33059999.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    15. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020 07 14; 4(13):2899-2911. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. PMID: 32589729; PMCID: PMC7362346.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    16. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nat Commun. 2020 04 22; 11(1):1931. Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. PMID: 32321912; PMCID: PMC7176739.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    17. Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2020 05; 26(5):876-883. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG. PMID: 31785375.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    18. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2020 03; 34(3):938-941. Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, Shah N, Wiita AP. PMID: 31595037; PMCID: PMC7214267.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    19. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma. Mol Cancer Ther. 2019 11; 18(11):2008-2020. Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L, Kamperschroer C, Pascua E, Chen W, Delaria K, Farias S, Bateman M, Dushin RG, Chin SM, Van Blarcom TJ, Yeung YA, Lindquist KC, Chunyk AG, Kuang B, Han B, Mirsky M, Pardo I, Buetow B, Martin TG, Wolf JL, Shelton D, Rajpal A, Strop P, Chaparro-Riggers J, Sasu BJ. PMID: 31434693.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    20. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 06; 25(6):1218-1224. Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL. PMID: 30708189.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    21. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. Mol Cancer Ther. 2017 11; 16(11):2375-2386. Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M. PMID: 28878026.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    22. Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports. Am J Kidney Dis. 2017 Jun; 69(6):858-862. Le TX, Wolf JL, Peralta CA, Webber AB. PMID: 28320553.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    23. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 12 01; 126(12):4640-4653. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. PMID: 27841764; PMCID: PMC5127683.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    24. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. PMID: 27587788; PMCID: PMC5524541.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    25. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Am J Hematol. 2016 Jun; 91(4):400-5. Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL. PMID: 26800393.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    26. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 05 26; 127(21):2561-8. Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. PMID: 26932802.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    27. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 06; 22(6):1030-1036. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. PMID: 26899561.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    28. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 07; 57(7):1560-6. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. PMID: 26490487.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. PMID: 25776193.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    30. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B. PMID: 25294123; PMCID: PMC4482758.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    31. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. PMID: 24894413.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    32. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Sep; 53(9):1820-3. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S. PMID: 22288662.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    33. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol. 2010 Aug; 150(4):428-37. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC. PMID: 20618338; PMCID: PMC3418598.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    34. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010 Jul; 24(7):1350-6. Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. PMID: 20508619; PMCID: PMC2957585.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    35. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol. 2010 Mar 11; 3:9. Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC. PMID: 20222977; PMCID: PMC2851575.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    36. Myeloma-associated polyneuropathy responding to lenalidomide. Neurology. 2009 Sep 08; 73(10):812-3. Layzer R, Wolf J. PMID: 19738177.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    37. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol. 2009 Sep; 146(6):619-26. Jagannath S, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A, Crowley J, Vescio R. PMID: 19622094.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    38. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005 Jun; 129(6):776-83. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J. PMID: 15953004.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    39. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant. 2002 Feb; 29(4):297-301. Linker CA, Damon LE, Ries CA, Navarro WA, Case D, Wolf JL. PMID: 11896426.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    40. Trisomy 4 and double minutes in acute myeloid leukemia: further evidence that double minutes can occur as the primary cytogenetic abnormality. Cancer Genet Cytogenet. 2000 Sep; 121(2):212-5. Govberg IJ, Wolf JL, Cotter PD. PMID: 11063811.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    41. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant. 2000 Aug; 26(3):257-68. Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA. PMID: 10967563.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    42. Monosomy 16 as the sole abnormality in myeloid malignancies. Cancer Genet Cytogenet. 2000 Apr 15; 118(2):163-6. McGhee EM, Cohen NR, Wolf JL, Ledesma CT, Cotter PD. PMID: 10748300.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    43. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. Biol Blood Marrow Transplant. 2000; 6(5):496-505. Damon LE, Hu WW, Stockerl-Goldstein KE, Blume KG, Wolf JL, Gold E, Cecchi GR, Irwin D, Glaspy J, Territo I, Miller W, Mason JR, Linker CA. PMID: 11063378.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    44. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant. 1998 Nov; 22(9):865-72. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. PMID: 9827814.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    45. Mismatches for two major and one minor histocompatibility antigen correlate with a patient's rejection of a bone marrow graft from a serologically HLA-identical sibling. Biol Blood Marrow Transplant. 1997 Nov; 3(5):255-60. Lienert-Weidenbach K, Valiante NM, Brown C, White C, Johnston-Dow L, McGinnis M, Krausa P, Lakes DM, Wolf JL, Blume KG, Parham P. PMID: 9450920.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    46. High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma. Prog Clin Biol Res. 1994; 389:505-11. Rugo HS, Damon LE, Ries CA, Wolf JL, Linker CA. PMID: 7535460.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    47. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. Semin Oncol. 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. Linker CA, Damon LE, Ries CA, Rugo HS, Wolf JL. PMID: 8342075.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993 Jan 15; 81(2):311-8. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. PMID: 8422457.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    49. Why antigens are attracted to the dome epithelium: another clue. Gastroenterology. 1988 Nov; 95(5):1419-21. Wolf JL. PMID: 3169506.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    50. Deficiency of protein 4.2 in erythrocytes from a patient with a Coombs negative hemolytic anemia. Evidence for a role of protein 4.2 in stabilizing ankyrin on the membrane. J Clin Invest. 1988 Mar; 81(3):893-901. Rybicki AC, Heath R, Wolf JL, Lubin B, Schwartz RS. PMID: 2963832; PMCID: PMC442542.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    51. Outcome of bone marrow transplantation in patients with extramedullary involvement of acute leukemia. Blut. 1984 Feb; 48(2):75-9. Spruce WE, Forman SJ, Krance RA, Farbstein MJ, Wolf JL, Scott EP, Nademanee AP, Fahey JL, Henke M, Blume KG. PMID: 6365207.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia. Blood. 1983 Mar; 61(3):439-42. Forman SJ, Spruce WE, Farbstein MJ, Wolf JL, Scott EP, Nademanee AP, Fahey JL, Hecht T, Zaia JA, Krance RA, Findley DO, Blume KG. PMID: 6337652.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    53. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infections in patients with prolonged neutropenia. Schweiz Med Wochenschr Suppl. 1983; 14:40-5. McCutchan JA, Wolf JL, Ziegler EJ, Braude AI. PMID: 6361990.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    54. Successful second bone marrow transplantation in a patient with myositis ossificans progressiva and aplastic anemia. Am J Pediatr Hematol Oncol. 1983; 5(4):337-40. Spruce WE, Forman SJ, Blume KG, Farbstein MJ, Scott EP, Wolf JL, Krance R. PMID: 6367519.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    55. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection. JAMA. 1982 Nov 12; 248(18):2301-3. Hecht T, Wolf JL, Mraz L, Scott EP, Patz LD. PMID: 6752444.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    56. Reversal of acute ("malignant") myelosclerosis by allogeneic bone marrow transplantation. Blood. 1982 Jan; 59(1):191-3. Wolf JL, Spruce WE, Bearman RM, Forman SJ, Scott EP, Fahey JL, Farbstein MJ, Rappaport H, Blume KG. PMID: 7032626.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    57. Experimental Hematology Today. Bone marrow transplantation for acute leukemia. 1982; 143-146. Blume, K.G., Forman, S.J., Spruce, W.E., Wolf, J.L., Farbstein, M.J., Scott, E.P., Fahey, J.L., Hecht, T., Findley, D.O., Hill, L.R., Paladugu, R.R., Petz, L.D. and Zaia, J.A.
    58. N. Engl. J. Med. Prevention and therapy for graft-vs-host disease. 1982; 307:376-377. Forman, S.J., Farbstein, M.J., Scott, E.P., Wolf, J.L., Spruce, W.E., Fahey, J.L., Nademanee, A. and Blume, K.G.
    59. Susceptibility of mice to rotavirus infection: effects of age and administration of corticosteroids. Infect Immun. 1981 Aug; 33(2):565-74. Wolf JL, Cukor G, Blacklow NR, Dambrauskas R, Trier JS. PMID: 6268547; PMCID: PMC350737.
      View in: PubMed   Mentions: 42     Fields:    Translation:AnimalsCells
    60. Bone-marrow transplantation for acute leukemia. N Engl J Med. 1981 Jul 09; 305(2):101-3. Blume KG, Spruce WE, Forman SJ, Wolf JL, Farbstein MJ, Scott EP, Fahey JL. PMID: 7017404.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Intestinal M cells: a pathway for entry of reovirus into the host. Science. 1981 Apr 24; 212(4493):471-2. Wolf JL, Rubin DH, Finberg R, Kauffman RS, Sharpe AH, Trier JS, Fields BN. PMID: 6259737.
      View in: PubMed   Mentions: 148     Fields:    Translation:AnimalsCells
    62. Terminal deoxynucleotidyl transferase-positive lymphadenopathy in acute-phase chronic granulocytic leukemia. Am J Clin Pathol. 1981 Mar; 75(3):403-6. Chillar RK, Wolf JL, Bearman RM, Teplitz RL. PMID: 6938125.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    63. Bone marrow ablation and marrow transplantation in acute leukemia: influence of clinical pretransplant condition. Transplant Proc. 1981 Mar; 13(1 Pt 1):252-3. Blume KG, Spruce WE, Forman SJ, Bross KJ, Beutler E, Farbstein MJ, Fahey JL, Schmidt GM, Scott EP, Wolf JL. PMID: 6267750.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    64. Combined idiopathic neutropenia and thrombocytopenia: evidence for an immune basis for the syndrome. Ann Intern Med. 1980 Nov; 93(5):704-7. Linker CA, Newcom SR, Nilsson CM, Wolf JL, Shuman MA. PMID: 7212480.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    65. Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med. 1980 May 08; 302(19):1041-6. Blume KG, Beutler E, Bross KJ, Chillar RK, Ellington OB, Fahey JL, Farbstein MJ, Forman SJ, Schmidt GM, Scott EP, Spruce WE, Turner MA, Wolf JL. PMID: 6245359.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    66. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med. 1979 Sep; 91(3):412-3. Wolf JL, Perkins HA, Schreeder MT, Vincenti F. PMID: 382937.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    67. Regulation of hemoglobin beta-chain synthesis in bone marrow erythroid cells by alpha chains. Proc Natl Acad Sci U S A. 1973 Dec; 70(12):3405-9. Wolf JL, Mason RG, Honig GR. PMID: 4519634; PMCID: PMC427246.
      View in: PubMed   Mentions: 5     Fields:    Translation:Cells
    Jeffrey's Networks
    Concepts (336)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (60)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.